Latest Breaking News On - European hematology association congress - Page 5 : comparemela.com

Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition

- New data including longer duration follow-up from SCD and TDT pivotal trials accepted for oral presentation – - Five additional abstracts accepted for poster presentation - .

United statesCity ofUnited kingdomExagamglogene autotemcelVertex pharmaceuticals incorporated nasdaqEuropean hematology association congressImprovements in healthCompanies to workOcclusive crisis on healthAmerican society of hematologyExchange commissionVertex pharmaceuticals incorporatedAnnual meetingSevere sickle cellHealth related qualityLife after exagamglogene autotemcel

FDA completes meeting for potential genetic therapy to treat sickle cell disease

FDA completes meeting for potential genetic therapy to treat sickle cell disease
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Carmen bozicEuropean hematology association congressGene therapies advisory committeeDrug administrationVertex pharmaceutical

Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma

The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies.

San diegoUnited statesNoord hollandVenclexta venclyxtoMariana cota stirnerInternational myeloma working groupEuropean hematology association congressWith pomdexCota stirnerDimopoulosm aHematology association congressPhase 3 canova study

Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOtsuka europeMartin bucklandAlison rossOtsuka pharmaceutical europe ltdTaiho oncology incTaiho pharmaceutical co ltdOtsuka pharmaceutical company ltdEuropean hematology association congressOtsuka holdings co ltdEuropean commissionAmerican society of hematology annual meetingEuropean medicines agencyOtsuka pharmaceutical co ltdAstex pharmaceuticals incPharmaceutical europe

Astex Pharmaceuticals, Inc : Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia

Astex Pharmaceuticals, Inc : Otsuka and Astex announce that the European Commission has approved INAQOVI (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAlison rossOtsuka europeMartin bucklandOtsuka holdings co ltdAstex pharmaceuticals incTaiho oncology incOtsuka pharmaceutical company ltdEuropean medicines agencyEuropean hematology association congressOtsuka pharmaceutical co ltdEuropean commissionOtsuka pharmaceutical europe ltdAmerican society of hematology annual meetingTaiho pharmaceutical co ltdOtsuka pharmaceutical europe